CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Total Non-Current Liabilities across 12 years of filings, most recently posting $898.0 million for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 185.89% year-over-year to $898.0 million; the TTM figure through Jun 2026 stood at $898.0 million (up 185.89% YoY), while the FY2025 annual figure was $337.3 million, up 10.04% from the prior year.
• Total Non-Current Liabilities came in at $898.0 million for Q2 2026 at CRISPR Therapeutics AG, down from $905.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $905.3 million in Q1 2026 to a low of $306.5 million in Q4 2024.
• Average Total Non-Current Liabilities over 5 years is $409.6 million, with a median of $353.8 million recorded in 2022.
• Year-over-year, Total Non-Current Liabilities fell 11.58% in 2025 and jumped 185.89% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $361.6 million in 2022, then declined by 4.37% to $345.8 million in 2023, then fell by 11.36% to $306.5 million in 2024, then climbed by 10.04% to $337.3 million in 2025, then jumped by 166.24% to $898.0 million in 2026.
• Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $898.0 million in Q2 2026, $905.3 million in Q1 2026, and $337.3 million in Q4 2025.